Atlas market file · Equity · United States
Kodiak Sciences Inc.KOD
- Last close
- 45.4
- Change
- +4.10%
- 96-bar range
- 21 – 47.84
- As of
- 6 Aug 2026
Kodiak Sciences Inc. is a biological products, (no diagnostic substances) issuer listed as KOD on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
KOD
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+1481.88% over the window).
Source rail: Yahoo Finance chart API (KOD). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for KOD. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
KOD public profile
Biological products, (no diagnostic substances) issuer. Kodiak Sciences Inc. is connected to current market context, cited company sources and its retained research file.
Kodiak Sciences Inc. trades as KOD on NASDAQ. Kodiak Sciences Inc. (KOD) has a latest verified close of 45.4, up 4.10%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files KOD under USA Stocks and Science & Biotech Stocks for browsing.
What changed for Kodiak Sciences Inc. today
Kodiak Sciences Inc. (KOD) opened the week reeling from its Q1 2026 financials: a $58.2 million net loss, $48.5 million in R&D spending, and zero revenue despite a $306 million asset base. The biotech’s Antibody Biopolymer Conjugate (ABC) Platform and tarcocimab tedromer (Zenkuda) candidates remain in clinical trials, with no approved products and a cash burn rate of $40 million per quarter. (source: SEC EDGAR 10-Q)
Kodiak’s financials paint a company living on borrowed time. With $169.5 million in cash but no path to revenue, the firm’s survival hinges on trial outcomes and potential partnerships. Its DAYBREAK study costs are rising, and competitors like Roche’s FDA-approved Vabysmo loom large. The 61.9 million diluted shares outstanding could grow further if insider selling continues, as six July 2026 Form 4 filings show executives unloading over 250,000 shares. (source: Press Release)
The company’s SEC filings reveal stark risks: high R&D costs, no commercial products, and a reliance on capital markets. Positive topline results from the GLOW2 trial (March 2026) offer hope, but the market awaits harder data. Kodiak’s $112.1 million equity base and $193.9 million liabilities suggest limited cushion. The source directs readers to catalysts like the DAYBREAK readout or partnership announcements, but the current evidence shows a company burning cash faster than it can file 8-Ks. (source: SEC EDGAR 10-Q, Form 4 filings)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
KOD technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on KOD
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep KOD research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
KOD FAQ
What is Kodiak Sciences Inc. (KOD)?Kodiak Sciences Inc. (KOD) has a latest verified close of 45.4, up 4.10%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Kodiak Sciences Inc. (KOD) has a latest verified close of 45.4, up 4.10%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for KOD?Kodiak Sciences Inc. (KOD) has a latest verified close of 45.4, up 4.10%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
Kodiak Sciences Inc. (KOD) has a latest verified close of 45.4, up 4.10%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files KOD under USA Stocks and Science & Biotech Stocks for browsing.
How often is the KOD page updated?The KOD public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The KOD public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for KOD?The KOD file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:KOD. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The KOD file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:KOD. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on KOD?Yes. The workstation can open KOD, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open KOD, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this KOD page investment advice?No. The KOD page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The KOD page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →